90 related articles for article (PubMed ID: 23241250)
1. [French Health Authority (HAS) Guidance: the post-registration studies on health technologies (drugs, medical devices and instruments): principles and methods].
Stamenkovic S; Solesse A; Zanetti L; Zagury P; Vray M;
Therapie; 2012; 67(5):409-21. PubMed ID: 23241250
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Stamenkovic S; Solesse A; Zanetti L; Zagury P; Vray M;
Therapie; 2012; 67(5):409-21. PubMed ID: 27393714
[TBL] [Abstract][Full Text] [Related]
3. Post-approval studies in France, challenges facing medical devices.
Levesque K; Coqueblin C; Guillot B; ; Aubourg L; Avouac B; Carbonneil C; Cucherat M; Descamps-Mandine P; Hanoka S; Goldberg M; Josseran A; Parquin F; Pitel S; Ratignier C; Sechoy O; Szwarcenstein K; Tanti A; Teiger E; Thevenet N
Therapie; 2014; 69(4):303-21. PubMed ID: 25230354
[TBL] [Abstract][Full Text] [Related]
4. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
5. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
6. How to improve the clinical development paradigm and its division into phases I, II and III.
Bamberger M; Moore N; Lechat P;
Therapie; 2011; 66(4):331-4, 327-30. PubMed ID: 21851796
[TBL] [Abstract][Full Text] [Related]
7. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
8. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
[TBL] [Abstract][Full Text] [Related]
9. Requests for post-registration studies (PRS), patients follow-up in actual practice: Changes in the role of databases.
Berdaï D; Thomas-Delecourt F; Szwarcensztein K; d'Andon A; Collignon C; Comet D; Déal C; Dervaux B; Gaudin AF; Lamarque-Garnier V; Lechat P; Marque S; Maugendre P; Méchin H; Moore N; Nachbaur G; Robain M; Roussel C; Tanti A; Thiessard F
Therapie; 2018 Feb; 73(1):13-24. PubMed ID: 29530314
[TBL] [Abstract][Full Text] [Related]
10. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
[TBL] [Abstract][Full Text] [Related]
11. [French Health Authority guide].
Bouvenot G; Dubernard JM; Rochaix L
Therapie; 2012; 67(5):407. PubMed ID: 23241249
[No Abstract] [Full Text] [Related]
12. Current French system of post-marketing drug surveillance.
Albengres E; Gauthier F; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
[TBL] [Abstract][Full Text] [Related]
13. Design and implementation of a portal for the medical equipment market: MEDICOM.
Palamas S; Kalivas D; Panou-Diamandi O; Zeelenberg C; van Nimwegen C
J Med Internet Res; 2001; 3(4):E32. PubMed ID: 11772547
[TBL] [Abstract][Full Text] [Related]
14. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
15. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
[TBL] [Abstract][Full Text] [Related]
16. [How to optimize the carrying out and the development of post-registration studies].
Borel T; Jouan-Flahault C;
Therapie; 2011; 66(6):469-72. PubMed ID: 22186071
[TBL] [Abstract][Full Text] [Related]
17. Design considerations in an active medical product safety monitoring system.
Gagne JJ; Fireman B; Ryan PB; Maclure M; Gerhard T; Toh S; Rassen JA; Nelson JC; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():32-40. PubMed ID: 22262591
[TBL] [Abstract][Full Text] [Related]
18. [French system of drug surveillance].
Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
[TBL] [Abstract][Full Text] [Related]
19. Ireland's competent authority initiatives.
Scully C
Stud Health Technol Inform; 1996; 28():101-11. PubMed ID: 10164084
[TBL] [Abstract][Full Text] [Related]
20. Quality analysis of medical device vigilance reports.
Sievänen H; Pommelin P
Technol Health Care; 2003; 11(4):275-81. PubMed ID: 14600338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
